Dr. Yu on Emerging Standards in Radiation for Prostate Cancer

James B. Yu, MD
Published: Monday, Apr 02, 2018



James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses emerging standards in radiation for the treatment of patients with prostate cancer.

The current standard is external beam radiation therapy, says Yu. Also, hydrogel spacer has spread rapidly and is a standard of care for prostate radiotherapy to space the rectum away from the prostate. Randomized studies now show a quality of life benefit for not only bowel toxicity, but urinary and sexual toxicity as well.

The other current standard is moderate hypofractionation. More evidence has not accrued, but as more physicians are using it and becoming comfortable with it, it is an option for patients. Three major large randomized studies show it is equivalent to standard fractionation for low- and intermediate-risk disease.
 


James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses emerging standards in radiation for the treatment of patients with prostate cancer.

The current standard is external beam radiation therapy, says Yu. Also, hydrogel spacer has spread rapidly and is a standard of care for prostate radiotherapy to space the rectum away from the prostate. Randomized studies now show a quality of life benefit for not only bowel toxicity, but urinary and sexual toxicity as well.

The other current standard is moderate hypofractionation. More evidence has not accrued, but as more physicians are using it and becoming comfortable with it, it is an option for patients. Three major large randomized studies show it is equivalent to standard fractionation for low- and intermediate-risk disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x